PFIZER INVESTMENT ENTERPRISES PTE. LTD., as Issuer PFIZER INC., as Parent Guarantor and THE BANK OF NEW YORK MELLON, as Trustee INDENTURE Dated as of May 19, 2023 DEBT SECURITIESIndenture • May 19th, 2023 • Pfizer Inc • Pharmaceutical preparations • New York
INDENTURE, dated as of May 19, 2023, among PFIZER INVESTMENT ENTERPRISES PTE. LTD., a private company limited by shares incorporated under the laws of the Republic of Singapore (the “Issuer”), PFIZER INC., a Delaware corporation (the “Parent Guarantor”), and THE BANK OF NEW YORK MELLON, a New York banking corporation, as trustee (the “Trustee”).
PFIZER INVESTMENT ENTERPRISES PTE. LTD., as Issuer PFIZER INC., as Parent Guarantor and THE BANK OF NEW YORK MELLON, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of May 19, 2023 to INDENTURE Dated as of May 19, 2023 4.650% Notes due 2025 4.450%...Pfizer Inc • May 19th, 2023 • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE, dated as of May 19, 2023 (the “First Supplemental Indenture”), among Pfizer Investment Enterprises Pte. Ltd., a private company limited by shares incorporated under the laws of the Republic of Singapore (the “Issuer”), Pfizer Inc., a Delaware corporation, as guarantor (the “Parent Guarantor”), and The Bank of New York Mellon, a New York banking corporation, as trustee (the “Trustee”).
Pfizer Investment Enterprises Pte. Ltd. Debt Securities Unconditionally Guaranteed on a Senior Unsecured Basis by Pfizer Inc. Underwriting AgreementPricing Agreement • May 19th, 2023 • Pfizer Inc • Pharmaceutical preparations
From time to time Pfizer Investment Enterprises Pte. Ltd., a private company limited by shares incorporated under the laws of the Republic of Singapore (the “Issuer”) and a wholly-owned subsidiary of Pfizer Inc., a Delaware corporation (the “Guarantor”), together with the Guarantor, proposes to enter into one or more Pricing Agreements (each a “Pricing Agreement”) in the form of Annex I hereto, with such additions and deletions as the parties thereto may determine, and subject to the terms and conditions stated herein and therein, to issue and sell to the firms named in Schedule I to the applicable Pricing Agreement (such firms constituting the “Underwriters” with respect to such Pricing Agreement and the securities specified therein) certain of its debt securities (the “Notes”) specified in Schedule II to such Pricing Agreement. Each of such Notes will have the benefit of an unconditional and irrevocable guarantee on a senior unsecured basis (the “Guarantee”) as to the payment of prin
PRICING AGREEMENTPricing Agreement • May 19th, 2023 • Pfizer Inc • Pharmaceutical preparations
Pfizer Investment Enterprises Pte. Ltd., a private company limited by shares incorporated under the laws of the Republic of Singapore (the “Issuer”) and a wholly-owned subsidiary of Pfizer Inc., a Delaware corporation (the “Guarantor”), together with the Guarantor, proposes, subject to the terms and conditions stated herein and in the Underwriting Agreement, dated May 16, 2023 (the “Underwriting Agreement”), among the Issuer, the Guarantor and the Representatives of the several Underwriters to issue and sell to each of the Underwriters named in Schedule I hereto (the “Underwriters”) the securities specified in Schedule II hereto (the “Notes”). Each of such Notes will have the benefit of an unconditional and irrevocable guarantee on a senior unsecured basis (the “Guarantee”) as to the payment of principal and interest from the Guarantor. The Notes and the Guarantee are referred to collectively in this Agreement as the “Designated Securities.” Each of the provisions of the Underwriting A
